GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD
GSK announced positive results from the MATINEE phase III trial, showing Nucala (mepolizumab) significantly reduced COPD exacerbations. Nucala targets IL-5 in type 2 inflammation, with consistent safety results. Full data will be presented at a future scientific congress.
Related Clinical Trials
Reference News
GSK's phase III trial MATINEE shows Nucala (mepolizumab) significantly reduces COPD exacerbations in patients with type 2 inflammation. Nucala targets IL-5, a key cytokine in type 2 inflammation, and preliminary safety results align with its known profile. Full results to be presented at a future scientific congress.
GSK's Nucala succeeded in a Phase 3 study for COPD patients with chronic bronchitis/emphysema, significantly reducing exacerbations. This follows a 2018 FDA rejection for lack of data. Nucala targets interleukin-5 and is already approved for severe asthma. GSK will discuss the new data with regulators and present it at a future medical meeting.
GSK's Phase III trials of depemokimab in severe asthma showed a 54% reduction in exacerbations and a 72% reduction in hospitalisations. Safety profile was similar to placebo, with no related deaths or serious AEs.
GSK announced positive results from the MATINEE phase III trial evaluating Nucala (mepolizumab) for COPD, showing a significant reduction in exacerbations. Nucala targets IL-5 and has a known safety profile.
GSK announced positive results from the MATINEE phase III trial evaluating Nucala, an IL-5-targeting monoclonal antibody, in adults with COPD, showing a significant reduction in moderate/severe exacerbations. The preliminary safety results align with Nucala's known profile.
GSK's phase III trial MATINEE showed Nucala (mepolizumab) significantly reduced COPD exacerbations in patients with type 2 inflammation. Nucala targets IL-5, key in type 2 inflammation, and preliminary safety results align with known profiles. Full results to be presented at a future scientific congress.
GSK's Phase III trials of depemokimab in severe asthma patients with elevated blood eosinophil counts showed a 54% reduction in exacerbations and a 72% reduction in hospitalisations or emergency visits. The treatment's safety profile was comparable to placebo.
GSK's asthma drug Nucala met primary endpoint in Phase III COPD trial, showing reduced exacerbations when added to inhaled maintenance therapy. GSK plans EU and Canada regulatory submission in 2025, with ongoing data analysis. Nucala, an IL-5 antagonist, generated £1.6bn in 2023 and is predicted to reach $2.35bn by 2026.
GSK's depemokimab reduced serious asthma attacks by 54% and hospitalizations by 72% in year-long trials, positioning it as a key growth driver with potential annual sales of £3 billion. The drug requires injections every six months, less frequent than competitors, and is being tested for other type 2 inflammatory conditions.
GSK announces positive results of MATINEE trial, showing Nucala (mepolizumab) significantly reduces COPD exacerbations in type 2 inflammation patients.
GSK reports positive MATINEE Phase 3 results for Nucala in COPD, showing significant reduction in exacerbations. Nucala targets IL-5 and is not yet approved for COPD globally.
GSK's MATINEE phase III trial showed Nucala, targeting IL-5, significantly reduced COPD exacerbations in adults with type 2 inflammation, with consistent safety.
GSK announced positive results from the MATINEE phase III trial, showing Nucala (mepolizumab) significantly reduced COPD exacerbations. Nucala targets IL-5 in type 2 inflammation, with consistent safety results. Full data will be presented at a future scientific congress.
GSK's ultra-long-acting biologic depemokimab, evaluated in Phase III trials for severe asthma, shows promise with two annual doses, reducing exacerbations and hospitalizations. It targets type 2 inflammation via high binding affinity for IL-5, with similar adverse event rates to placebo.
Depemokimab, an ultra-long-acting biologic targeting IL-5, showed significant reduction in asthma exacerbations in 2 phase 3 trials (SWIFT-1 and SWIFT-2) for severe asthma with type 2 inflammation. The therapy met primary and key secondary endpoints, including reducing hospitalizations and emergency visits, though quality-of-life improvements were not statistically significant. Depemokimab, with 6-month dosing intervals, could be the first of its kind approved, offering potential benefits for severe asthma management.
GSK announced positive results from the MATINEE phase III trial evaluating Nucala (mepolizumab) for COPD, showing a significant reduction in moderate/severe exacerbations. Nucala targets IL-5, key in type 2 inflammation, and is currently not indicated for COPD.
GSK's asthma drug Nucala met primary endpoint in Phase III COPD trial, reducing exacerbations when added to inhaled therapy. GSK anticipates EU and Canada regulatory submission in 2025. Nucala, an IL-5 antagonist, generated £1.6bn in 2023 and is predicted to reach $2.35bn by 2026.
GSK's phase III trial for Nucala in treating COPD met primary endpoint, showing significant reduction in exacerbations. Nucala, targeting type 2 inflammation, is not yet indicated for COPD. Full results to be presented at a future scientific congress.
GSK announced positive Phase III MATINEE trial results for Nucala, showing a reduction in COPD exacerbations. Nucala, a monoclonal antibody targeting IL-5, is currently approved for severe asthma and other conditions but not COPD. GSK plans to present full trial findings and share results with health authorities. The COPD market is anticipating potential approvals for Sanofi and Regeneron's Dupixent and Verona's Ohtuvayre.
GSK’s depemokimab, an ultra-long-acting biologic, significantly reduced severe asthma exacerbations by 54% over one year in phase 3 trials, with a 72% reduction in hospitalisations or emergency visits. Despite non-significant improvements in quality of life, the data supports global regulatory filings.
Depemokimab reduces severe asthma attacks by over 50% and hospitalizations by 72% in phase 3 trials, published in The New England Journal of Medicine. Administered twice yearly, it targets IL-5 to inhibit type 2 inflammation, offering a dosing schedule beneficial to patients managing multiple therapies.
GSK announces positive phase III trial results for Nucala (mepolizumab) in COPD, showing significant reduction in exacerbations.
GSK’s Nucala (mepolizumab) significantly reduced moderate and severe COPD exacerbations in the Phase III MATINEE trial. Nucala targets IL-5 to reduce type 2 inflammation, previously approved for eosinophilic asthma and other conditions. The trial involved 806 COPD patients with elevated blood eosinophil counts, adding Nucala or placebo to optimized maintenance therapy. GSK plans to present full MATINEE data at a future congress, aiming to inform regulatory discussions for Nucala’s approval in COPD.
GSK's MATINEE Phase 3 trial showed Nucala (mepolizumab) significantly reduced COPD exacerbations in type 2 inflammation patients, with safety consistent with known profile. Nucala is not yet indicated for COPD but contributed 6% to GSK's 2023 sales.
GSK’s long-acting asthma treatment, depemokimab, reduced serious attacks by 54% and hospitalizations/ER visits by 72% in Phase III trials. Despite missing secondary endpoints, the drug’s primary goal of reducing exacerbations was achieved. Depemokimab, an anti-IL-5 therapy, is part of GSK’s planned 12 major product launches, expected to generate £38 billion by 2031, with peak sales of £3 billion. Administered twice yearly, it aims to address unmet needs in severe asthma treatment.
ERS Congress 2024 presented advancements in asthma treatment, focusing on type 2 inflammation. David Jackson's SWIFT trials showed depemokimab reduced severe asthma exacerbations by 58% and 48% in SWIFT-1 and SWIFT-2, respectively, with no waning effect. Leonard Bacharier's VOYAGE study revealed dupilumab increased clinical remission rates in children with uncontrolled asthma, from 0% at baseline to 42% with dupilumab vs. 24% with placebo.
SWIFT-1 and SWIFT-2 phase III data show depemokimab significantly reduces asthma exacerbations over 52 weeks versus placebo. Depemokimab, an ultra-long-acting biologic, administered once every six months, sustained suppression of type 2 inflammation, a key driver of asthma attacks and hospitalisations. Data published in the New England Journal of Medicine.